Assays and methods for identifying serum biomarkers for the diagnosis of Alzheimer's disease (AD): Isolation of plasma proteins and isobaric protein tagging and LC/MS/MS analysis, Characterization of biomarkers by Western blotting , Validation of selected biomarkers using Selective Reaction Monitoring (SRM)

< Previous Protocol
Assays and methods for evaluating the efficacy of immunization against beta-amyloid (Abeta) for the treatment of Alzheimers disease (juvenile non-human primate (NHP) model): Analysis of antibody response to vaccinations by detecting anti-Abeta42 antibodies, Histopathologic evaluation and [11C]PiB positron emission tomography imaging of Abeta content in the brain, Analyses of amyloid load and oligomer species using ELISA and western blot, Assessment of microglial activation using [11C]PK11195 positron emission tomography imaging, Microglial quantification by immunohistochemistry and real-time PCR, Analysis of immune activation marker YKL40 release in the cerebrospinal fluid (CSF), Multiplex analysis of chemokines in CSF

Next Protocol >
Assays and methods for screening modulators of nicotinic acetylcholine receptors (nAChRs) for treating Alzheimer's disease and neuropsychiatric diseases: CNS nAChRs: Alpha 4 Beta 2 NNR Subtype Radioligand Binding Assays Using Membranes from Rat Cortex and SH-EP1/human alpha 4 beta 2 clonal cells, CNS nAChRs: Alpha 7 NNR Subtype Inhbition Binding Assay With [3H]MLA Using Rat Hippocampal Proteins, Drug Selectivity Assay for Human Ganglionic nAChR Subtype and Human Muscle nAChR Subtype, Memory Test Using a Three-Trial Object Recognition Test, Working Memory Assessment Using a Radial Arm Maze (RAM) Task, CYP Inhibition Studies (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4), In Vitro Secondary Pharmacology: Multiple Receptor Screening Assay, hERG Inhibition Assay

Related Protocols
View all Neurodegenerative disease biomarker and drug discovery protocols
Assays and methods for screening the efficacy of electromagnetic field (EMF) exposure in reversing very advanced brain Abeta aggregation/deposition in mouse models: EMF treatment, Behavioral Testing, Open field activity to measure exploratory behavior and general activity, Balance beam to measure balance and general motor function, Y-maze spontaneous alternation to measure general activity and basic mnemonic function, Circular platform to measure spatial/reference learning and memory, RAWA task of spatial working memory, Visual Cliff to evaluate vision/depth perception, Body/brain temperature determinations, rCBF determinations in cerebral cortex, Abeta immunohistochemistry and image analysis, Determination of Abeta140 and 142 levels in plasma samples using ELISA, Statistical analysis
Assays and methods for the identification of splice variants (e.g. syndecan-2 splice variants) as a molecular diagnositc biomarkers of Alzheimer's disease: Identification and characterization of Syndecan-2 Splice Variants Using Comprehensive Bioinformatic Analyses and Electronic hybridization, Detection of Splice Variants in Alzheimer's Disease Brains Using RT-PCR, DNA Sequence Analysis of splice Variants and Comparison of Relative Levels of Splice Variant RNA in Brain, Cloning and Expression and Purification of Recombinant Splice Variant Protein and Generation of Polyclonal Antibodies, Analysis of the Effect of Splice Variants in Secretions of Beta Cleavage Products of APP in HEK293E Cell Cultures Using Western Blotting, Immunolocalization of the Splice Variant to the Neurofibrillary Tangles of Alzheimer's Disease
Assays and methods for screening compounds that are modulators of gamma secretase for treating Alzheimer's disease: Secretase Reaction and A beta Analysis in Whole Cells, MS Analysis of A beta Profile, CSF A beta Analysis, Matrix-assisted laser desorption/ionization mass spectrometric (MALDI MS) analysis of A beta
Assays and methods for screening N-methyl-D-aspartic acid (NMDA) receptor potentiators for treating neurodegenerative diseases, neuropsychiatric diseases and neurological diseases: NMDA Receptor Activity Assay Using Recombinant NMDA Receptors, Activity at Native NMDA Receptor Responses in Neurons from Basal Ganglia Slices, Potentiation of Homomeric GluR1 AMPA Receptors, Evaluation Human Ether-a-Go-Go Potassium Channel (hERG) Binding, Metabolic Stability Studies Using Pooled Human or Rat Liver Microsomes, High Throughput Bioassay to Identify Selective Modulators of NR2C- or NR2D-containing receptors
Assays and methods of screening compounds that decrease the activity of tetrahydrobiopterin (BH4) by increasing the expression of GTPCH-binding or activity of GTP cyclohydrolase feedback regulatory protein (GFRP) for treating neuropathic pain: Tissue and RNA Preparation from DRG, Microarray Analysis Using Affymetrix Rat Genome U34A Oligonucleotide Microarrays, Isotopic in Situ Hybridization of DRGs, GTP Cyclohydrolase I (GTPCH) Activity Assays by Measuring Biopterin or Neopterin Levels Using Fluorometric, radiolabel, Immunoassay, Spectrophotometry, and HPLC Techniques